The results indicate that E. coli infection modulates the pharmacokinetics of orally administered enrofloxacin by increasing intestinal P-gp expression and decreasing CYP3A expression in the liver and kidney of broilers. The gene discussed is CYP3A4; the disease is escherichia coli infection.